Embecta Corp. (EMBC) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Parsippany, NJ, 미국. 현재 CEO는 Devdatt Kurdikar.
EMBC 을(를) 보유 IPO 날짜 2022-03-22, 2,000 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $560.22M.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
